GlassScriptPhysician profile
Kenneth L Klein
NPI 1174507990
$8,320.84
in general payments reported to CMS, 2019-2025
23 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $413 · 2021: $987 · 2022: $1,752 · 2023: $1,687 · 2024: $1,313 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,874 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.74 |
| Education | $285.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,770.34 | 2019-2025 | |
| Genzyme Corporation | $1,097.88 | 2020-2025 | |
| Janssen Biotech, INC. | $949.55 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $592.99 | 2019-2023 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $241.23 | 2020-2025 | Ilumya, Blu-U |
| Leo Pharma INC. | $201.59 | 2022-2023 | Adbry |
| Amgen INC. | $197.93 | 2024 | Otezla |
| Almirall LLC | $147.11 | 2021 | |
| Prugen, INC. Pharmaceuticals | $143.05 | 2019 | |
| Pfizer INC. | $142.02 | 2020-2025 | |
| Genentech USA, INC. | $140.19 | 2022-2024 | Erivedge, Xolair |
| Janssen Scientific Affairs, LLC | $125.79 | 2022-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $125.17 | 2023-2025 | Sotyktu |
| Celgene Corporation | $85.81 | 2019 | |
| Lilly USA, LLC | $82.13 | 2021-2024 | Olumiant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $80.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.21 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.74 | 2019 | |
| Organogenesis INC. | $31.57 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $16.99 | 2019 | |
| Dermira, INC. | $13.86 | 2020 | |
| Galderma Laboratories, L.P. | $13.76 | 2025 | Nemluvio |
| Organon LLC | $10.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.